研究業績（原著論文のみ）/ Publications(Original Articles only)
2021年度
KRAS inhibitor-resistance in MET-amplified KRAS G12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms.
Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, Haratani K, Tanizaki J, Kawakami H, Hayashi H, Sakai K, Nishio K, Nakagawa K.
Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7.
Curcumin β-D-glucuronide modulates an autoimmune model of multiple sclerosis with altered gut microbiota in the ileum and feces
Khadka S, Omura S, Sato F, Nishio K, Kakeya H,
Front Cell Infect Microbiol. 2021 Dec 3;11:772962. doi: 10.3389/fcimb.2021.772962. eCollection 2021.
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S, Haratani K, Hayashi H, Chiba Y, Tanizaki J, Kato R, Mitani S, Kawanaka Y, Kurosaki T, Hasegawa Y, Okabe T, Tanaka K, Akashi Y, Ozaki T, Nishio K, Ito A, Nakagawa K.
Eur J Cancer. 2022 Jan;161:44-54. doi: 10.1016/j.ejca.2021.11.011. Epub 2021 Dec 15. PMID: 34922263.
Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis.
Sakai K, Sakurai T, De Velasco MA, Nagai T, Chikugo T, Ueshima K, Kura Y, Takahama T, Hayashi H, Nakagawa K, Kudo M, Nishio K.
Front Oncol. 2021 Oct 27;11:763468. doi: 10.3389/fonc.2021.763468. PMID: 34778085; PMCID: PMC8578892.
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.
Fujino T, Suda K, Sakai K, Murakami I, Shimizu S, Ohara S, Koga T, Hamada A, Soh J, Nishio K, Mitsudomi T.
Clin Lung Cancer. 2021 Sep 24:S1525-7304(21)00246-1. doi: 10.1016/j.cllc.2021.09.005. Epub ahead of print. PMID: 34702670.
The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.
Hatanaka Y, Kuwata T, Morii E, Kanai Y, Ichikawa H, Kubo T, Hatanaka KC, Sakai K, Nishio K, Fujii S, Okamoto W, Yoshino T, Ochiai A, Oda Y.
Pathol Int. 2021 Nov;71(11):725-740. doi: 10.1111/pin.13170. Epub 2021 Oct 6. PMID: 34614280.
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.
Osoegawa A, Yamaguchi M, Nakamura T, Morinaga R, Tanaka K, Kashiwabara K, Miura T, Suetsugu T, Harada T, Asoh T, Taguchi K, Nabeshima K, Kishimoto J, Sakai K, Nishio K, Sugio K.
JTO Clin Res Rep. 2021 May 14;2(7):100191. doi: 10.1016/j.jtocrr.2021.100191. PMID: 34590037; PMCID: PMC8474195.
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset.
Nishio K, Seto T, Nishio M, Reck M, Garon EB, Sakai K, Goto K, Kato T, Nakanishi Y, Takahashi T, Yamamoto N, Kiura K, Ohe Y, Tamura T, Visseren-Grul C, Frimodt-Moller B, Hozak RR, Wijayawardana SR, Zimmermann A, Homma G, Enatsu S, Nakagawa K.
JTO Clin Res Rep. 2021 Apr 16;2(6):100171. doi: 10.1016/j.jtocrr.2021.100171. PMID: 34590023; PMCID: PMC8474372.
Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial.
Imamura Y, Tanaka K, Kiyota N, Hayashi H, Ota I, Arai A, Iwae S, Minami S, Yane K, Yamazaki T, Nagatani Y, Toyoda M, Takahama T, Sakai K, Nishio K, Otsuki N, Nibu KI, Minami H.
Med Oncol. 2021 Sep 22;38(11):128. doi: 10.1007/s12032-021-01581-z. PMID: 34550483.
Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer.
De Velasco MA, Kura Y, Ando N, Sako N, Banno E, Fujita K, Nozawa M, Yoshimura K, Sakai K, Yoshikawa K, Nishio K, Uemura H.
Cancers (Basel). 2021 Aug 6;13(16):3975. doi: 10.3390/cancers13163975. PMID: 34439133; PMCID: PMC8391912.
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.
Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Nishio K, Kobayashi Y, Kakimi K, Kudo M.
Liver Cancer. 2021 Jul;10(4):380-393. doi: 10.1159/000516899. Epub 2021 Jun 9. PMID: 34414125; PMCID: PMC8339510.
Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model.
Sakai K, De Velasco MA, Kura Y, Nishio K.
Cancers (Basel). 2021 Jul 22;13(15):3683. doi: 10.3390/cancers13153683. PMID: 34359585; PMCID: PMC8345192.
Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.
Hirokawa E, Watanabe S, Sakai K, Takeda M, Sato C, Takahama T, Nishio K, Nakagawa K.
Thorac Cancer. 2021 Aug;12(16):2283-2287. doi: 10.1111/1759-7714.14081. Epub 2021 Jul 9. PMID: 34240806; PMCID: PMC8365001.
Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
Murakami K, Kanto A, Sakai K, Miyagawa C, Takaya H, Nakai H, Kotani Y, Nishio K, Matsumura N
Mod Pathol. 2021 Nov;34(11):2071-2079. doi: 10.1038/s41379-021-00861-3. Epub 2021 Jun 25. PMID:
34172890; PMCID: PMC8514336.
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA.
Sunami K, Bando H, Yatabe Y, Naito Y, Takahashi H, Tsuchihara K, Toyooka S, Mimori K, Kohsaka S, Uetake H, Kinoshita I, Komine K, Takeda M, Hayashida T, Tamura K, Nishio K, Yamamoto N; Working Group of a Joint Task Force of Three Academic Societies for the Promotion of Cancer Genomic Medicine.
Cancer Sci. 2021 Sep;112(9):3911-3917. doi: 10.1111/cas.15022. Epub 2021 Jul 12.
PMID: 34128569; PMCID: PMC8409307.
CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Kato R, Hayashi H, Sakai K, Suzuki S, Haratani K, Takahama T, Tanizaki J, Nonagase Y, Tanaka K, Yoshida T, Takeda M, Yonesaka K, Kaneda H, Nishio K, Nakagawa K.
Int J Clin Oncol. 2021 Sep;26(9):1628-1639. doi: 10.1007/s10147-021-01947-3. Epub 2021 Jun 11. PMID:
34117553.
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer.
Watanabe S, Takeda M, Otani T, Yoshida T, Sakai K, Olek E, Rothenberg SM, Kherani J, French PP, Nishio K, Ito A, Nakagawa K.
JCO Precis Oncol. 2021 Jan 11;5:PO.20.00282. doi: 10.1200/PO.20.00282. PMID: 34036231; PMCID: PMC8140803.
Guidelines for clinical evaluation of anti- cancer drugs.
Minami H, Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, Fuse N, Kuboki Y, Shimizu T, Yamamoto N, Nishio K, Kawakami Y, Nihira SI, Sase K, Nonaka T, Takahashi H, Komori Y, Kiyohara K.
Cancer Sci. 2021 Jul;112(7):2563-2577. doi: 10.1111/cas.14967. Epub 2021 Jun 8. PMID: 33990993; PMCID: PMC8253284.
Implementation of clinical sequencing for molecular profiling in patients with advanced cancer
Fukui T, Sakai K, Sasaki J, Kakegawa MI, Igawa S, Mitsufuji H, Takeda M, Takahama T, Nakagawa K, Nishio K, Naoki K.
Cancer Biomark. 2021;31(2):119-126. doi: 10.3233/CBM-200781. PMID: 33896820.
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in
mice: potential role of cancer-associated fibroblasts.
Kato R, Haratani K, Hayashi H, Sakai K, Sakai H, Kawakami H, Tanaka K, Takeda M, Yonesaka K, Nishio K, Nakagawa K.
Br J Cancer. 2021 Mar;124(5):914-924. doi: 10.1038/s41416-020-01201-z. Epub 2020 Dec 10. PMID:
33299131; PMCID: PMC7921555.
Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1).
Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, Kinoshita I, Kiyota N, Kohno T, Kohsaka S, Komine K, Matsumura I, Miura Y, Nakamura Y, Natsume A, Nishio K, Oda K, Oda N, Okita N, Oseto K, Sunami K, Takahashi H, Takeda M, Tashiro S, Toyooka S, Ueno H, Yachida S, Yoshino T, Tsuchihara K; Japanese Society of Medical Oncology; Japan Societyof Clinical Oncology; Japanese Cancer Association.
Int J Clin Oncol. 2021 Feb;26(2):233-283. doi: 10.1007/s10147-020-01831-6. Epub 2020 Nov 29. PMID: 33249514; PMCID: PMC7819967.
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Sakai K, Tsuboi M, Kenmotsu H, Yamanaka T, Takahashi T, Goto K, Daga H, Ohira T, Ueno T, Aoki T, Nakagawa K, Yamazaki K, Hosomi Y, Kawaguchi K, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Okabe K, Yamamoto N, Nishio K.
Cancer Sci. 2021 Jan;112(1):388-396. doi: 10.1111/cas.14730. Epub 2020 Nov 30. PMID: 33185928; PMCID: PMC7780021.
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K, Takahama T, Shimokawa M, Azuma K, Takeda M, Kato T, Daga H, Okamoto I, Akamatsu H, Teraoka S, Ono A, Ohira T, Yokoyama T, Yamamoto N, Nakagawa K, Nishio K.
Mol Oncol. 2021 Jan;15(1):126-137. doi: 10.1002/1878-0261.12841. Epub 2020 Nov 17. PMID: 33131198; PMCID: PMC7782093.
Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.
Suda K, Sakai K, Obata K, Ohara S, Fujino T, Koga T, Hamada A, Soh J, Nishio K, Mitsudomi T.
Clin Lung Cancer. 2021 Mar;22(2):e141-e145. doi: 10.1016/j.cllc.2020.09.009. Epub 2020 Sep 18. PMID:
33051123.
Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy.
Goda K, Murao T, Handa Y, Katsumata R, Fukushima S, Nakato R, Osawa M, Ishii M, Fujita M, Handa O, Matsumoto H, Fujita Y, Nishio K, Wallace TM, Gomez- Esquivel R, Berzosa M, Wolfsen HC, Wallace MB, Umegaki E, Shiotani A.
Esophagus. 2021 Apr;18(2):306-314. doi: 10.1007/s10388-020-00762-5. Epub 2020 Jul 29. PMID: 32728973.
Integrin‑linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma
Shimizu S, Sakai K, Chikugo T, Satou T, Shiraishi N, Mitsudomi T, Nishio K.
Oncol Lett
. 2021 Apr;21(4):320. doi: 10.3892/ol.2021.12582. Epub 2021 Feb 23.
PDZK1 induces resistance to apoptosis in esophageal adenocarcinoma cells
Handa O, Goda K, Handa Y, Fukushima S, Osawa M, Murao T, Matsumoto H, Umegaki E, Fujita Y, Nishio K, Shiotani A.
Esophagus
. 2021 Jul;18(3):655-662. doi: 10.1007/s10388-021-00819-z. Epub 2021 Feb 14.
A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review
Miyagawa C, Takaya H, Sakai K, Nishio K, Konishi M, Minamiguchi S, Shimada T, Matsumura N.
Oncologist
. 2021 May;26(5):356-361. doi: 10.1002/onco.13714. Epub 2021 Feb 22.
Genetic profile of adult T-cell leukemia/lymphoma in Okinawa:
Association with prognosis, ethnicity, and HTLV-1 strains
Sakihama S, Morichika K, Saito R, Miyara M, Miyagi T, Hayashi M, Uchihara J, Tomoyose T, Ohshiro K, Nakayama S, Nakachi S, Morishima S, Sakai K, Nishio K, Masuzaki H, Fukushima T, Karube K.
Cancer Sci
. 2021 Mar;112(3):1300-1309. doi: 10.1111/cas.14806. Epub 2021 Jan 31.
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors
Takeda M, Takahama T, Sakai K, Shimizu S, Watanabe S, Kawakami H, Tanaka K, Sato C, Hayashi H, Nonagase Y, Yonesaka K, Takegawa N, Okuno T, Yoshida T, Fumita S, Suzuki S, Haratani K, Saigoh K, Ito A, Mitsudomi T, Handa H, Fukuoka K, Nakagawa K, Nishio K.
Oncologist
. 2021 Apr;26(4):e588-e596. doi: 10.1002/onco.13639. Epub 2021 Jan 6.
Real-world Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan
Yatabe Y, Yoshiki Y, Matsumura K, Togo K, Kikkawa H, Iadeluca L, Li B, Nishio K.
JTO Clin Res Rep. 2020 Dec 29;2(3):100136. doi: 10.1016/j.jtocrr.2020.100136. eCollection 2021 Mar.
2020年度
Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
Komeda Y, Sakurai T, Sakai K, Morita Y, Hashimoto A, Nagai T, Hagiwara S, Matsumura I, Nishio K, Kudo M.
World J Clin Cases
. 2020 Dec 26;8(24):6389-6395. doi: 10.12998/wjcc.v8.i24.6389.
Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study
Ohara S, Suda K, Sakai K, Nishino M, Chiba M, Shimoji M, Takemoto T, Fujino T, Koga T, Hamada A, Soh J, Nishio K, Mitsudomi T.
Transl Lung Cancer Res
. 2020 Oct;9(5):1915-1923. doi: 10.21037/tlcr-20-505.
Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact
Noguchi T, Iwahashi N, Sakai K, Matsuda K, Matsukawa H, Toujima S, Nishio K, Ino K.
Cancers (Basel)
. 2020 Nov 16;12(11):3382. doi: 10.3390/cancers12113382.
Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis.
Sakurai T, Nishiyama H, Sakai K, De Velasco MA, Nagai T, Komeda Y, Kashida H, Okada A, Kawai I, Nishio K, Ogata H, Kudo M.
Sci Rep
. 2020 Nov 5;10(1):19186. doi: 10.1038/s41598-020-76175-2.
Site-specific and Molecular Guided Targeted Therapy Based on Gene Profiling using Next Generation Sequencing for Patients with Cancer of Unknown Primary Site: A Non-Randomized Phase 2 Clinical Trial.
Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K.
JAMA Oncol
. 2020 Dec 1;6(12):1931-1938. doi: 10.1001/jamaoncol.2020.4643.
Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis.
Honobe A, Sakai K, Togashi Y, Ohnuma T, Kawamura T, Nishio K, Inozume T.
J Dermatol Sci
. 2020 Dec;100(3):217-219. doi: 10.1016/j.jdermsci.2020.09.004. Epub 2020 Sep 24.
BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
Kondo T, Kanai M, Matsubara J, Quy PN, Fukuyama K, Yamamoto Y, Yamada T, Nishigaki M, Minamiguchi S, Takeda M, Nishio K, Matsumoto S, Muto M.
Pancreas
. Nov/Dec 2020;49(10):e101-e103. doi: 10.1097/MPA.0000000000001672.
Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.
Nishida N, Sakai K, Morita M, Aoki T, Takita M, Hagiwara S, Komeda Y, Takenaka M, Minami Y, Ida H, Ueshima K, Nishio K, Kudo M.Liver Cancer
Liver Cancer.10.1159/000506352. 2020 Mar
17
Multiplex Gene-panel Testing for Lung Cancer Patients.
Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H.
Pathol Int
. 2020 Dec;70(12):921-931. doi: 10.1111/pin.13023. Epub 2020 Sep 21.
A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood.
Kawanaka Y, Kawakami H, Shimizu S, Yoshida T, Hayashi H, Nishio K, Satou T, Nakagawa K.
Case Rep Oncol
. 2020 Jul 14;13(2):843-848. doi: 10.1159/000508362. eCollection May-Aug 2020.
Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.
Suda K, Murakami I, Obata K, Sakai K, Fujino T, Koga T, Ohara S, Hamada A, Soh J, Nishio K, Mitsudomi T.
Lung Cancer
. 2020 Oct;148:100-104. doi: 10.1016/j.lungcan.2020.08.010. Epub 2020 Aug 22.
Bioinformatics Analysis of Gut Microbiota and CNS Transcriptome in Virus-Induced Acute Myelitis and Chronic Inflammatory Demyelination; Potential Association of Distinct Bacteria with CNS IgA upregulation.
Omura S, Sato F, Park AM, Fujita M, Khadka S, Nakamura Y, Katsuki A, Nishio K, Gavins FNE, Tsunoda I.
Front Immunol
. 2020 Jul 7;11:1138. doi: 10.3389/fimmu.2020.01138. eCollection 2020.
Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression.
Sakai H, Takeda M, Sakai K, Nishio K, Nakagawa K.
Mol Clin Oncol
. 2020 Aug;13(2):175-178. doi: 10.3892/mco.2020.2048. Epub 2020 May 21.
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Shimizu T, Nishio K, Sakai K, Okamoto I, Okamoto K, Takeda M, Morishita M, Nakagawa K.
Cancer Chemother Pharmacol
. 2020 Aug;86(2):211-219. doi: 10.1007/s00280-020-04112-1. Epub 2020 Jul 8.
Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer.
Noguchi T, Sakai K, Iwahashi N, Matsuda K, Matsukawa H, Yahata T, Toujima S, Nishio K, Ino K.
Oncol Lett
. 2020 Apr;19(4):2713-2720. doi: 10.3892/ol.2020.11356. Epub 2020 Jan 28.
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K.
Cancer
. 2020 Jan 1;126(9):1940-1948. doi: 10.1002/cncr.32749. Epub 2020 Feb 5.
Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
Ishii H, Azuma K, Sakai K, Naito Y, Matsuo N, Tokito T, Yamada K, Hoshino T, Nishio K.
Sci Rep
. 2020 Jan 20;10(1):691. doi: 10.1038/s41598-020-57624-4.
U3-1402 sensitizes HER3-expressing
tumors to PD-1 blockade by immune activation.
Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, Kawakami
H, Tanaka K, Hayashi H, Takeda M, Maeda N, Kagari T, Hirotani K, Tsurutani J,
Nishio K, Doi K, Miyazawa M, Nakagawa K.
J Clin Invest
. 2020 Jan 2;130(1):374-388. doi: 10.1172/JCI126598.